You are here: Home » Companies » News
Business Standard

Alembic Pharma gets tentative USFDA nod for breast cancer treatment drug

Drug firm Alembic Pharmaceuticals said it has received tentative approval from the US health regulator for Palbociclib capsules, used to treat a certain type of breast cancer

Topics
Alembic Pharmaceuticals | breast cancer drug | USFDA

Press Trust of India  |  New Delhi 

Medical illustration : Pills of all kinds, shapes and colours
Representative photo of pills

Drug firm on Monday said it has received tentative approval from the US health regulator for Palbociclib capsules, used to treat a certain type of breast cancer.

The approved product is therapeutically equivalent to the reference listed drug product lbrance Capsules of Pfizer Inc.

"The company has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) in the strengths of Palbociclib capsules, 75 mg, 100 mg, and 125 mg," said in a regulatory filing.

Alembic said it is currently in litigation with Pfizer in District Court of Delaware and launch of the product will depend on litigation outcome.

Citing IQVIA data, Alembic Pharma said Palbociclib capsules, 75 mg, 100 mg, and 125 mg, have an estimated market size of USD 624 million for 12 months ending June 2020.

Alembic Pharma now has a total of 135 ANDA approvals (117 final approvals and 18 tentative approvals) from

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, November 09 2020. 11:49 IST
RECOMMENDED FOR YOU
.